FDA Authorizes Novavax’s COVID-19 Vaccine for Emergency Use

Published on: 

Company expects treatment to be available across the country.

Novavax Inc. revealed that the FDA has officially cleared its COVID-19 vaccine under an emergency use authorization (EUA). Previously, the treatment was recommended by the CDC in September. With doses expected to be available at thousands of locations such as national and local retail pharmacies, the vaccine is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product.


"COVID-19 is once again on the rise with infections and hospitalizations increasing, so it's important that individuals get vaccinated to protect themselves and their loved ones," said John C. Jacobs, president, CEO, Novavax, in a company press release. "Novavax's authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19, which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine."

Reference: Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the US. Novavax. October 3, 2023. Accessed October 5, 2023. https://ir.novavax.com/press-releases/2023-10-03-Novavax-2023-2024-COVID-19-Vaccine-Now-Authorized-and-Recommended-for-Use-in-the-U-S